BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10559086)

  • 21. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.
    Ladfors SW; Lindahl JK; Hansson S; Brandström P; Andersson R; Jertborn M; Lindh M; Woxenius S; Friman V
    Pediatr Nephrol; 2020 Mar; 35(3):427-439. PubMed ID: 31802220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
    Calabrese F; Loy M; Lunardi F; Marino D; Aversa SM; Rea F
    Transpl Infect Dis; 2010 Aug; 12(4):342-6. PubMed ID: 20030794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
    Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O
    Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation.
    Montone KT; Litzky LA; Wurster A; Kaiser L; Bavaria J; Kotloff R; Palevsky H; Pietra GG; Tomaszewski JE
    Surgery; 1996 May; 119(5):544-51. PubMed ID: 8619211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
    Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL
    Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus infection in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Johnson SL; Klapper PE; Vallely PJ; Picton ML
    Am J Transplant; 2014 Jul; 14(7):1619-29. PubMed ID: 24815922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.
    Höcker B; Fickenscher H; Delecluse HJ; Böhm S; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Billing H; Fichtner A; Feneberg R; Sander A; Köpf-Shakib S; Süsal C; Tönshoff B
    Clin Infect Dis; 2013 Jan; 56(1):84-92. PubMed ID: 23042966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.
    Sato T; Fujieda M; Maeda A; Tanaka E; Miyamura M; Chikamoto H; Hisano M; Akioka Y; Ishiura Y; Dohno S; Hattori M; Wakiguchi H
    Clin Nephrol; 2008 Nov; 70(5):393-403. PubMed ID: 19000539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
    Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY; Tait B; Levvey B; Griffiths A; Esmore DS; Snell GI; Williams TJ; Kotsimbos TC
    Transplantation; 2004 Jul; 78(2):205-10. PubMed ID: 15280679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A; Dierickx D; Verbeken EK; Tousseyn T; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verleden GM; Van Raemdonck DE; Vos R
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
    Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epstein-Barr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation : A Cohort Study.
    Ruijter BN; Wolterbeek R; Hew M; van Reeven M; van der Helm D; Dubbeld J; Tushuizen ME; Metselaar H; Vossen ACTM; van Hoek B
    Ann Intern Med; 2023 Feb; 176(2):174-181. PubMed ID: 36645888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
    Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
    Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
    Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.